• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Novo Nordisk A>Novo Nordisk A/S ADR

Novo Nordisk A/S ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. Investing
  1. Sanofi Shakes Off Patent Losses

    The drugmaker faces less long-term volatility as the focus shifts to steady businesses.

  2. Finding a Margin of Safety in a Fully Valued Market

    These three wide-moat firms are trading at reasonable prices in a market with little breathing room in valuations.

  3. 6 Key Concepts to Stock Investing Defined

    From moats to fair value to stewardship, we explain the key pillars of our approach to equities.

  4. A Preview of the 2014 Morningstar International-Stock Fund Manager of the Year Competition

    These managers are potential contenders for this year's honor.

  5. A Preview of the 2014 Morningstar International-Stock Fund Manager of the Year Competition

    These managers are potential contenders for this year's honor.

  6. Moats and Growth Drivers Look Solid for Post-Split Baxter

    Focus remains on hemophilia competition, but Baxter's comprehensive product portfolios are unmatched.

  7. Makings of a Wide Moat in Diabetes Care

    Novel products will allow drug firms to achieve price premiums on diabetes drugs in the U.S. and at least retain level pricing internationally.

  8. Strong Pipeline Helps Protect Baxter's Wide Moat From Competition

    The diversified health-care firm remains remarkably profitable in tough industries.

  9. Novo Nordisk Has One of the Widest Moats in Health Care

    Morningstar StockInvestor editor Matt Coffina explains why he recently purchased Novo Nordisk for StockInvestor's real-money Hare portfolio.

  10. Wide Moats, Positive Moat Trends, Exemplary Stewardship

    Morningstar StockInvestor editor Matt Coffina highlights three of the highest-quality companies we cover.

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.